Abzena PLC 'Abzena inside' product study data to be presented (9229P)
November 23 2016 - 3:09AM
UK Regulatory
TIDMABZA
RNS Number : 9229P
Abzena PLC
23 November 2016
Abzena plc
'Abzena inside' product clinical study data to be presented at
upcoming conference
Cambridge, UK, 23 November 2016 - Abzena plc (AIM: ABZA,
'Abzena' or the 'Group'), a life sciences group providing services
and technologies enabling the development and manufacture of
biopharmaceutical products, notes that Opsona Therapeutics Ltd
('Opsona') has announced that preliminary results from its ongoing
Phase I/II study of 'Abzena inside' product OPN-305 in second line
lower risk myelopdysplastic syndrome ('MDS') patients will be
presented at the 58th Annual Meeting of the American Society of
Hematology (ASH) in San Diego on 3 December 2016.
OPN-305 is a Toll-like receptor 2 (TLR-2) antibody being
developed by Opsona, having been created using Abzena's Composite
Human Antibody technology.
The conclusion of the interim analysis of the study was that
treatment with OPN-305 in patients with previously treated
lower-risk MDS was well tolerated with no significant toxicities
and a 50% overall response rate (ORR). The ASH abstract is now
online and can be accessed here:
https://ash.confex.com/ash/2016/webprogram/Paper97931.html
Lead principal investigator Professor Guillermo Garcia-Manero,
University of Texas MD Anderson Cancer Center, will present the
preliminary data at ASH and has commented in Opsona's announcement
that, "Inhibition of TLR2 with OPN-305 is safe and is currently
demonstrating strong clinical activity in patients with lower risk
MDS after hypomethylating agent therapy."
Enquiries:
Abzena plc
John Burt, Chief Executive
Officer
Julian Smith, Chief Financial
Officer +44 1223 903498
Numis (Nominated Adviser and
Broker) +44 20 7260
Clare Terlouw / Paul Gillam 1000
N+1 Singer (Joint Broker) +44 20 7496
Aubrey Powell / Liz Yong 3000
Instinctif Partners +44 20 7457 2020
Melanie-Toyne Sewell / Rozi abzena@instinctif.com
Morris
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and
complementary services to enable the development and manufacture of
biopharmaceutical products, a growing area that requires specialist
knowledge and expertise. The Group has a global customer base which
includes the majority of the top 20 biopharmaceutical companies as
well as large and small biotech companies and academic groups.
The term "Abzena inside" is used by Abzena to describe products
that have been created using its proprietary technologies and are
being developed by its partners, and include Composite Human
Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs).
Abzena has the potential to earn future licence fees, milestone
payments and/or royalties on "Abzena inside" products.
Abzena offers the following services and technologies across its
principal sites in Cambridge (UK), San Diego, California (USA) and
Bristol, Pennsylvania (USA).
-- Immunogenicity assessment, protein engineering to create
humanized antibodies and deimmunised therapeutic proteins, and cell
line development for manufacture.
-- Contract process development and manufacture of
biopharmaceuticals, including monoclonal antibodies, recombinant
proteins, vaccines, and gene therapy and cell therapy products, for
preclinical and clinical studies.
-- Proprietary site-specific conjugation technologies for
antibody drug conjugate development and solutions for optimizing
the therapeutic properties of biopharmaceuticals.
-- Contract chemistry and bioconjugation business focused on
ADCs and is establishing the capability to manufacture ADCs to GMP
standards.
For more information, please see www.abzena.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBJBPTMBMTMRF
(END) Dow Jones Newswires
November 23, 2016 03:09 ET (08:09 GMT)
Abzena (LSE:ABZA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abzena (LSE:ABZA)
Historical Stock Chart
From Apr 2023 to Apr 2024